CCM
KRTX

Cribstone Capital Management’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Cribstone Capital Management’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-10
Closed -$1K – 470
2021
Q4 		$1K Hold
10
– – ﹤0.01% 388
2021
Q3 		$1K Hold
10
– – ﹤0.01% 370
2021
Q2 		$1K Buy
+10
New +$1.17K ﹤0.01% 331

Other funds holding KRTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return

Cribstone Capital Management's KRTX Position: Q1 2022 in Review

Cribstone Capital Management sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2022, closing a stake of 10 shares — an estimated $1K sold.

Cribstone Capital Management first reported a position in KRTX in Q2 2021 and held it in 3 quarters. The position peaked at $1K in Q4 2021. 177 funds tracked by Wall St. Rank hold KRTX as of Q1 2022.

  • Cribstone Capital Management reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Cribstone Capital Management sold 10 Karuna Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $1K.
  • Cribstone Capital Management first reported a position in Karuna Therapeutics, Inc. Common Stock in Q2 2021 and held it in 3 quarters.
  • Cribstone Capital Management's Karuna Therapeutics, Inc. Common Stock position peaked at $1K in Q4 2021.
  • 177 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Cribstone Capital Management's 13F filing for Q1 2022, filed 16 May 2022.